Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker VRCA · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Oct 23, 2026 | Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2) NCT07246590 · Common Warts, Common Warts (Verruca Vulgaris) VP-102, Vehicle | VRCA Verrica Pharmaceuticals Inc. | Phase 3 | Active, not recruiting | 302 | Nov 2026 | Registry ↗ |
| Oct 22, 2026 | Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Ve… NCT07457918 · Common Warts (Verruca Vulgaris), Common Warts Cantharidin | VRCA Verrica Pharmaceuticals Inc. | Phase 3 | Recruiting | 250 | Nov 2027 | Registry ↗ |
| Oct 20, 2026 | Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris) (C… NCT07881952 · Common Warts, Common Warts (Verruca Vulgaris) VP-102 | VRCA Verrica Pharmaceuticals Inc. | Phase 2 | Not yet recruiting | 30 | Apr 2027 | Registry ↗ |
| Sep 3, 2026 | Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-3) NCT07637734 · Common Warts, Common Warts (Verruca Vulgaris) VP-102 (US) / TO-208 (Japan), Vehicle (US) / Vehicle (Japan) | VRCA Verrica Pharmaceuticals Inc. | Phase 3 | Recruiting | 300 | May 2027 | Registry ↗ |
| Jun 18, 2025 | Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma NCT05188729 · Basal Cell Carcinoma, Skin Cancer Part 1: VP-315 3 Day Dosing/Week, Part 2: VP-315 3 Day Dosi… | VRCA Verrica Pharmaceuticals Inc. | Phase 2 | Completed | 92 | Apr 15, 2024 | Registry ↗ |
| Nov 27, 2024 | A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts NCT03981822 · Condylomata Acuminata, Papillomavirus Infections VP-102 and applicator, Placebo | VRCA Verrica Pharmaceuticals Inc. | Phase 2 | Completed | 105 | May 21, 2020 | Registry ↗ |
| Nov 27, 2024 | Cantharidin and Occlusion in Verruca Epithelium NCT03487549 · Common Wart, Warts Hand VP-102 Cantharidin topical film forming solution, VP-102 Ca… | VRCA Verrica Pharmaceuticals Inc. | Phase 2 | Completed | 56 | May 16, 2019 | Registry ↗ |
| Jan 11, 2022 | Cantharidin Application in Molluscum Patients-1 NCT03377790 · Molluscum Contagiosum VP-102 - Cantharidin, Topical Film Forming Solution, Placeb… | VRCA Verrica Pharmaceuticals Inc. | Phase 3 | Completed | 266 | Nov 26, 2018 | Registry ↗ |
| Dec 14, 2021 | Cantharidin Application in Molluscum Patients NCT03377803 · Molluscum Contagiosum VP-102 - Cantharidin, Topical Film Forming Solution, Placeb… | VRCA Verrica Pharmaceuticals Inc. | Phase 3 | Completed | 262 | Sep 26, 2018 | Registry ↗ |
| Aug 11, 2021 | Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum. NCT03186378 · Molluscum Contagiosum VP-102 with applicator | VRCA Verrica Pharmaceuticals Inc. | Phase 2 | Completed | 33 | Jun 25, 2018 | Registry ↗ |
10 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 10:11 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances